Skip to search formSkip to main contentSkip to account menu

PRX302

Known as: PORxin 302, PRX 302 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Bacterial ToxinsPSA-PAH1

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Investigational procedures in benign prostatic hypertrophy
Purpose of review As benign prostatic hypertrophy (BPH) becomes a more common disease, there has been a dramatic rise in the… 
Review
2015
Review
2015
Intraprostatic injections for lower urinary tract symptoms treatment
Purpose of review The purpose of this study is to review and discuss recently published (2013–2014) experimental and clinical… 
Review
2015
Review
2015
Anesthesia-free procedures for benign prostate obstruction: worth it?
Purpose of review Perhaps, 30% of patients with benign prostate obstruction experience no symptom relief with drug therapy… 
Review
2013
Review
2013
Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia.
Review
2013
Review
2013
Treatment of lower urinary tract symptoms: Agents for intraprostatic injection
Abstract When the currently available pharmacotherapeutic principles used for treatment of male lower urinary tract symptoms… 
2012
2012
Neue Behandlungskonzepte von Symptomen des unteren Harntraktes beim Mann
ZusammenfassungAls Goldstandard in der medikamentösen Therapie von Patienten mit Beschwerden des unteren Harntraktes („lower… 
Review
2010
Review
2010
Emerging drugs for the treatment of benign prostatic obstruction
Importance of the field: Benign prostatic enlargement (BPE) leading to benign prostatic obstruction (BPO) affects an increasing… 
2009
2009
MP-06.13: PRX302 is a Transperineally Administered, PSA-Activated Protoxin that Produces Symptomatic Relief in Men with Moderate to Severe BPH
2008
2008
SU‐GG‐J‐145: Physics Support for Intraprostatic Treatment of Patients with Locally Recurrent Prostate Cancer with the PSA‐Activated Protoxin PRX302
Purpose: PRX302 is a protoxin in which the native furin‐cleaved pro‐domain has been modified to be proteolytically cleaved by PSA… 
Highly Cited
2007
Highly Cited
2007
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease.
BACKGROUND Most men will develop prostatic abnormalities, such as benign prostatic hyperplasia (BPH) or prostate cancer, as they… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)